Publications by authors named "Debra de Angelo"
Exploring the healthcare costs and resource use among privately insured US patients with post-traumatic stress disorder (PTSD). This study used Merative MarketScan data. The index date was defined as the first PTSD claim.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the cost-effectiveness of MDMA-assisted therapy (MDMA-AT) for chronic PTSD against a placebo with therapy (PT) using a health state-transition model.
- MDMA-AT costs about $64,745 and generates 3.691 quality-adjusted life years (QALYs), while PT costs $33,132 and yields 3.314 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of $83,845 per QALY.
- To remain within a $150,000 willingness-to-pay threshold, the maximum allowed cost for the MDMA sessions was determined to be $20,314 each, showing that MDMA-AT offers better utility and lower PTSD
Objective: This retrospective claims analysis explored the treatment utilization and characteristics among patients with post-traumatic stress disorder (PTSD) of different severity.
Methods: The index date was the first PTSD claim. The analysis observed 12 months pre- and 24 months post-index.